API
< Back to all clusters
[HEALTH] · 2 sources

started · updated

Researchers identify new prolactin receptor target for lupus treatment

Medical researchers have identified a potential new therapeutic target for systemic lupus erythematosus (SLE) by focusing on the prolactin receptor (PRLR). The study, published in Experimental and Molecular Medicine, suggests that an imbalance in the isoforms of this receptor contributes to the autoimmune behavior seen in lupus patients.

Investigators found that immune cells in individuals with lupus exhibit a significantly higher proportion of the long variant of the receptor compared to the short variants. This imbalance helps trigger and maintain the destructive immune responses characteristic of the disease.

In animal models, the experimental strategy of targeting this specific receptor variant reduced inflammatory molecular signals and protected kidney tissue. Notably, the approach appeared to spare healthy immune cells, offering a more selective alternative to current broad immunosuppressive drugs and corticosteroids, which often leave patients vulnerable to infections by disabling normal immune defenses.

Entities

City of Hope · Experimental and Molecular Medicine · University of California, Riverside